alexa Alveolar Hemorrhage Associated with Rivaroxaban: A Case
ISSN: 2161-105X

Journal of Pulmonary & Respiratory Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Alveolar Hemorrhage Associated with Rivaroxaban: A Case Series

Heather Laird-Fick, Brian J Grondahl*, Megan Benedict and Anas Riehani

Department of Internal Medicine, Michigan State University, East Lansing, MI, USA

*Corresponding Author:
Brian J Grondahl
Department of Internal Medicine, Michigan State University
788 Service Road, Room B301, East Lansing, MI, USA
Tel: 5173535100
E-mail: [email protected]

Received date: April 17, 2017; Accepted date: May 09, 2017; Published date: May 13, 2017

Citation: Laird-Fick H, Grondahl BJ, Benedict M, Riehani A (2017) Alveolar Hemorrhage Associated with Rivaroxaban: A Case Series. J Pulm Respir Med 7:405. doi: 10.4172/2161-105X.1000405

Copyright: © 2017 Laird-Fick H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Background: We present 4 cases of alveolar hemorrhage in patients receiving rivaroxaban. While bleeding is a common complication of rivaroxaban therapy reported by multiple case reports in the literature, this complication is not frequently reported. There were two cases of alveolar hemorrhage related to rivaroxaban found in our literature search. Alveolar hemorrhage is a potentially fatal complication and must be promptly recognized.

Case Presentation: The electronic medical record was reviewed for patients with alveolar hemorrhage syndromes admitted to our hospital between July 1, 2014 and June 30, 2015. This data was cross referenced for patients received anticoagulant medications.

Our series of patients included one patient with underlying Antiphospholipid Syndrome (APS) and systemic lupus erythematous, another patient with pulmonary malignancy and distant lung resection, a third patient with lymphangioleiomyomatosis, and a fourth patient with myelodysplastic syndrome. Rivaroxaban accounted for 13.6% of all cases of clinically significant pulmonary hemorrhage and drug related pulmonary hemorrhage accounted for half of cases. The rate of alveolar hemorrhage associated with Rivaroxaban in our institution was about 3 cases in 1000.

Conclusions: We identified four cases of rivaroxaban associated alveolar hemorrhage. We encourage cautious use of rivaroxaban in patients with underlying lung conditions or factors that predispose to alveolar hemorrhage. Further research to clarify the risk of diffuse alveolar hemorrhage (DAH) in at-risk patients receiving oral anticoagulants is recommended.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version